Connection
Michael Bristow to Cardiomyopathies
This is a "connection" page, showing publications Michael Bristow has written about Cardiomyopathies.
|
|
Connection Strength |
|
 |
|
 |
|
1.898 |
|
|
|
-
Doran B, Mei C, Varosy PD, Kao DP, Saxon LA, Feldman AM, DeMets D, Bristow MR. The Addition of a Defibrillator to?Resynchronization Therapy Decreases?Mortality in Patients With Nonischemic Cardiomyopathy. JACC Heart Fail. 2021 06; 9(6):439-449.
Score: 0.584
-
Taylor MR, Bristow MR. Alterations in myocardial gene expression as a basis for cardiomyopathies and heart failure. Novartis Found Symp. 2006; 274:73-83; discussion 83-9, 152-5, 272-6.
Score: 0.201
-
Mallabone M, Labib D, Abdelhaleem A, Dykstra S, Thompson RB, Paterson DI, Thompson SK, Hasanzadeh F, Mikami Y, Rivest S, Flewitt J, Feng Y, Macdonald M, King M, Bristow M, Kolman L, Howarth AG, Lydell CP, Miller RJH, Fine NM, White JA. Sex-based differences in the phenotypic expression and prognosis of idiopathic non-ischaemic cardiomyopathy: a cardiovascular magnetic resonance study. Eur Heart J Cardiovasc Imaging. 2024 May 31; 25(6):804-813.
Score: 0.180
-
Bristow MR. Why does the myocardium fail? Insights from basic science. Lancet. 1998 Aug; 352 Suppl 1:SI8-14.
Score: 0.120
-
Bristow MR. Tumor necrosis factor-alpha and cardiomyopathy. Circulation. 1998 Apr 14; 97(14):1340-1.
Score: 0.118
-
Eichhorn EJ, Bristow MR. Medical therapy can improve the biological properties of the chronically failing heart. A new era in the treatment of heart failure. Circulation. 1996 Nov 01; 94(9):2285-96.
Score: 0.107
-
Bristow MR, Feldman AM. Changes in the receptor-G protein-adenylyl cyclase system in heart failure from various types of heart muscle disease. Basic Res Cardiol. 1992; 87 Suppl 1:15-35.
Score: 0.076
-
Mazzini M, Tadros T, Siwik D, Joseph L, Bristow M, Qin F, Cohen R, Monahan K, Klein M, Colucci W. Primary carnitine deficiency and sudden death: in vivo evidence of myocardial lipid peroxidation and sulfonylation of sarcoendoplasmic reticulum calcium ATPase 2. Cardiology. 2011; 120(1):52-8.
Score: 0.076
-
Bristow MR, Kantrowitz NE, Ginsburg R, Fowler MB. Beta-adrenergic function in heart muscle disease and heart failure. J Mol Cell Cardiol. 1985 Jul; 17 Suppl 2:41-52.
Score: 0.049
-
Kantrowitz NE, Bristow MR. Cardiotoxicity of antitumor agents. Prog Cardiovasc Dis. 1984 Nov-Dec; 27(3):195-200.
Score: 0.046
-
Bristow MR, Billingham ME, Mason JW. Adriamycin cardiotoxicity. Am J Cardiol. 1984 Jan 01; 53(1):263-4.
Score: 0.044
-
Bristow MR, Mason JW, Billingham ME, Daniels JR. Dose-effect and structure-function relationships in doxorubicin cardiomyopathy. Am Heart J. 1981 Oct; 102(4):709-18.
Score: 0.037
-
Bristow MR, Minobe WA, Billingham ME, Marmor JB, Johnson GA, Ishimoto BM, Sageman WS, Daniels JR. Anthracycline-associated cardiac and renal damage in rabbits. Evidence for mediation by vasoactive substances. Lab Invest. 1981 Aug; 45(2):157-68.
Score: 0.037
-
Chung MK, Zidar DA, Bristow MR, Cameron SJ, Chan T, Harding CV, Kwon DH, Singh T, Tilton JC, Tsai EJ, Tucker NR, Barnard J, Loscalzo J. COVID-19 and Cardiovascular Disease: From Bench to Bedside. Circ Res. 2021 04 16; 128(8):1214-1236.
Score: 0.036
-
Braunwald E, Bristow MR. Congestive heart failure: fifty years of progress. Circulation. 2000 Nov 14; 102(20 Suppl 4):IV14-23.
Score: 0.035
-
Noori A, Lindenfeld J, Wolfel E, Ferguson D, Bristow MR, Lowes BD. Beta-blockade in adriamycin-induced cardiomyopathy. J Card Fail. 2000 Jun; 6(2):115-9.
Score: 0.034
-
Richardson P, McKenna W, Bristow M, Maisch B, Mautner B, O'Connell J, Olsen E, Thiene G, Goodwin J, Gyarfas I, Martin I, Nordet P. Report of the 1995 World Health Organization/International Society and Federation of Cardiology Task Force on the Definition and Classification of cardiomyopathies. Circulation. 1996 Mar 01; 93(5):841-2.
Score: 0.025
-
Raynolds MV, Bristow MR, Bush EW, Abraham WT, Lowes BD, Zisman LS, Taft CS, Perryman MB. Angiotensin-converting enzyme DD genotype in patients with ischaemic or idiopathic dilated cardiomyopathy. Lancet. 1993 Oct 30; 342(8879):1073-5.
Score: 0.022
-
Deisher TA, Narita H, Zera P, Ginsburg R, Bristow MR, Billingham ME, Fowler MB, Hoffman BB. Protective effect of clentiazem against epinephrine-induced cardiac injury in rats. J Pharmacol Exp Ther. 1993 Jul; 266(1):262-9.
Score: 0.021
-
Torti FM, Bristow MR, Howes AE, Aston D, Stockdale FE, Carter SK, Kohler M, Brown BW, Billingham ME. Reduced cardiotoxicity of doxorubicin delivered on a weekly schedule. Assessment by endomyocardial biopsy. Ann Intern Med. 1983 Dec; 99(6):745-9.
Score: 0.011
-
Bristow MR. Toxic cardiomyopathy due to doxorubicin. Hosp Pract (Off Ed). 1982 Dec; 17(12):101-8, 110-1.
Score: 0.010
-
Kantrowitz NE, Bristow MR, Minobe WA, Billingham ME, Harrison DC. Histamine-mediated myocardial damage in rabbits. J Mol Cell Cardiol. 1982 Sep; 14(9):551-5.
Score: 0.010
-
Bristow MR, Billingham ME, Mason JW, Daniels JR. Clinical spectrum of anthracycline antibiotic cardiotoxicity. Cancer Treat Rep. 1978 Jun; 62(6):873-9.
Score: 0.007
-
O'Connell JB, Bristow MR, Hammond EH, Menlove RL, Ensley RD, Ratkovec RM, Renlund DG. Antimurine antibody to OKT3 in cardiac transplantation: implications for prophylaxis and retreatment of rejection. Transplant Proc. 1991 Feb; 23(1 Pt 2):1157-9.
Score: 0.004
-
Lurie KG, Bristow MR, Minobe WA, Masek M, Billingham ME. 6-Hydroxydopamine mediated cardiotoxicity in rabbits. Am J Cardiovasc Pathol. 1988; 2(2):181-91.
Score: 0.004
-
Billingham ME, Mason JW, Bristow MR, Daniels JR. Anthracycline cardiomyopathy monitored by morphologic changes. Cancer Treat Rep. 1978 Jun; 62(6):865-72.
Score: 0.002
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|